Cantel Medical (CMD) 8-K Regulation FD Disclosure

Exhibit 99.1

 Cantel Medical Corp. (NYSE: CMN) Infection Control Matters™ 09-13-2011 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements. All forward-looking statements involve risks and uncertainties, including, without limitation, the risks detailed in the Company’s filings and reports with the Securities and Exchange Commission. Such statements are only predictions, and actual events or results may differ materially from those projected. CROSSTEX

2 Cantel Medical Corp. $345M NYSE Leader in Infection Prevention & Control1 Pure-play in a ~$35 billion Infection Prevention & Control Market (“IP&C”) Large, highly fragmented opportunities for growth and further expansion 17 acquisitions since 2001 have re-shaped the company Recession buffered markets as customers continue to invest resources and dollars Reimbursement at risk for providers not meeting IP&C standards Growing cash-generative core business with strong future upside and intermittent opportunistic spikes Leading share in every niche (endoscopy, water, dental disposables, and dialysis) 70% of consolidated sales are recurring1 5-year compound annual growth of 15% in sales and 19% in diluted EPS2 $60 million in EBITDAS (17% margin) and 2.0x leverage on balance sheet1 $0.12/share annual dividend Thrive in regulated arenas with disposables and equipment w/ proprietary consumables 90+% of products are made in the USA to ensure ongoing compliance Three-prong approach to growth via acquisitions, new product development and sales & marketing capabilities Throughout economic downturn invested heavily, especially in endoscopy, which now has an 80-person direct U.S. sales team 1 Pro forma for acquisition of Byrne Medical, Inc., which closed on August 1, 2011. Data reflects LTM ended 6/30/2011. 2 FYE 7/31/2005 – 7/31/2010.

3 Cantel Medical Corp. ~$35B Global Infection Prevention & Control Market Global IP&C Market (2006 US$M) U.S. Infection Prevention & Control Market (US$B) Forecast CAGR% 2006-2016 = 3.9% Infections in Medical Facilities are a Rapidly Growing Problem Annually, 2.3 Million People Acquire Infections in U.S. Medical Facilities and 99,000 Die From Those Infections1 -- More than AIDS, Breast Cancer and Traffic Accidents Combined Globally, 50+% of ICU patients have infections associated with an increased risk of death1 Adds as much as $20 Billion in U.S. healthcare costs1 and $5.5 Billion in Insurance Costs2 Growing awareness of infection risk in professional and consumer psyche H1N1 (“Swine” Flu), MRSA, C.Diff, Staph Infections, etc 1 Infection Control Today, 12/1/2009 referencing the 12/2/2009 issue of JAMA. 2 Donald Wright M.D., M.P.H., Principal Deputy Assistant Secretary for Health, U.S. Department of Health and Human Services, December 2008. Centers for Disease Control and Prevention (CDC) as cited in Healthcare Purchasing News, November 2005, Vol.29, No.11. and “A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000”, Patricia Stone, RN, PhD. Data Source: Freedonia Market Research. 2009F Japan $2,040 6% Other Asia/Pac $2,110 7% Rest of the World $2,970 9% Canada & Mexico $920 3% United States $13,840 45% Western Europe $7,690 24% China $2,040 6% $0.0 $2.0 $4.0 $6.0 $8.0 $10.0 $12.0 $14.0 $16.0 $18.0 $20.0 $22.0 US$ Billions 2001 2006 2011 2016 Consumables & Disposables Equipment Services

4 Cantel Medical Corp. Fragmented Nature of Infection Prevention & Control Indicates Cantel product offering Key strategic priorities Disinfectants & Cleaners Disposables Masks / Headwear Air & Water Quality Protective Apparel Brushes Disposable kits / trays Face shields Air filtration systems Aprons / bibs / arm protectors Dispensers Disposable medical products Masks Germicidal air cleaners Gloves Enzymatic cleaners Disposable surgical products Nurse/MD/Surg/Lab Hats Negative pressure isolation Lab gowns Medical device disinfectants Protection goggles Smoke evacuators Overshoes / coated boots Surface disinfectants Respirators Toxic gas detection systems Shirt jackets Wipes Wrap around lenses Water purification systems Surgical gowns 6 7 8 9 10 Sterilization Drapes & Barrier Products Hand Hygiene Wound Care & Closures Needles / Sharps / Transport Autoclaves Antimicrobial linens Automated hand washers Adhesives / adhesive removers Antimicrobial catheters Chemical sterilizers Fluid control drapes Hand cleaners / soaps Antimicrobial dressings Blood pressure cuff covers EtO sterilizers General purpose drapes Hand sanitizers (waterless) Dressings Catheter securement devices Low temperature sterilizers Surgical drapes Drains / suction Dispenser boxes Medical device drying cabinets  Hydrogel adhesive dressings Needle protection devices Medical device reprocessing  Silver bandages / dressings Safety I.V. catheters Steam sterilizing units  Surgical site skin prep Specimen transport bags Sterilization containers Sterilization packaging Washers / decontaminators Sterilization Services 11 12 13 14 15 Quality Control & Testers Fluid / Temperature/ Positioning Medical Waste & Cleaning Equipment Environmental Surveillance / Software / Education Biological indicators Filtration systems Antimicrobial casters Antimicrobial paint Alert systems Chemical integrators Fluid control systems Cleaning carts Containment systems Handwashing EtO monitors Fluid warming systems Decontamination equip Washable keyboards Surveillance software Glutaraldehyde monitors Forced air warming Infectious waste bags Pest management Training Respirator fit testers Patient positioning Microfiber mops Rapid MRSA diagnostics Sterility assurance products Pressure mgmt systems Room decontaminators Temperature mgmt kits Sharps containers Solidifiers / Spill Kits Suction canister systems Waste management systems

5 Cantel Medical Corp. Healthcare Reform Creates Greater Emphasis in IP&C Financial Penalties to Hospitals1 Preventable Readmissions – Estimated $25 billion cost to the system Beginning 2012, Medicare will stop paying hospitals for preventable readmissions tied to heart failure or pneumonia Beginning 2014, expand policy to cover four (4) more conditions Reduced Payment for Hospital Acquired Conditions – Infections & Errors Beginning 2012, Medicare will align actual payment to reported performance on patient satisfaction and care quality Beginning 2015, Dept. of Health & Human Services will start reporting each hospitals’ record for infections and medical errors pertaining to Medicare patients Payments reduced by 1% for those with highest rate of infections & medical errors No longer pay for treatment when a Medicaid patient is harmed during a hospital stay Despite Shrinking Budgets, Hospitals Maintain IP&C Funding2 2/3rds decreased or froze spending in 2009 and expect further cuts in 2010 However, virtually none cut patient safety infection control budgets in 2009, and spending growth is expected in the future 1 Healthcare Purchasing News, April 30, 2010. 2 HealthLeaders Media, April 6, 2010 – citation of LEK Hospital Purchasing Survey of January 2010 – Survey of 203 U.S. hospital CEOs, CFOs, COOs, materials managers, and purchasing directors.

6 Cantel Medical Corp. Three Synergistic Platforms Infection Prevention & Control Focus Healthcare & Life Sciences Orientation IP&C Device Management Endoscopy & Renal Dialysis Medivators/Byrne; Minntech Purification & Filtration Water Treatment & Therapeutic Filters Mar Cor Purification; Minntech Disposable Products Dental & Specialty Packaging Crosstex; Saf-T-Pak

7 Cantel Medical Corp. Well-Balanced Portfolio with Emphasis on Endoscopy Twelve Months Ended April 30, 20111 1 “All Other” includes Therapeutic Filtration Products. Specialty Packaging Products, and Chemistries. 2 Before allocation of corporate expenses of ~$8.9M. 3 Earnings Before Interest, Taxes, Depreciation, Amortization, Stock Compensation Expense and (Gain)/Loss on Disposal of Fixed Asset. The effect of rounding may create minor data variances. Net Sales $305.4M $344M pro forma for acquisition of Byrne Medical on Aug 1, 2011 Operating Income $40.7M2 $52M pro forma for acquisition of Byrne Medical on Aug 1, 2011 EBITDAS = $47.3M3 $60M pro forma for acquisition of Byrne Medical on Aug 1, 2011 $131.2 38% $24.0M 46% Water Purification & Filtration $87.9 26% Endoscopy (BMI Acquisition) $38.6 11% Healthcare Disposables $67.6 20% Dialysis $39.1 11% Endoscopy $92.6 27% All Other $18.2 5% Endoscopy (BMI Acquisition) $11.5 22% Water Purification & Filtration $7.6 14% Healthcare Disposables $9.3 18% All Other $1.8 3% Endoscopy $12.5 25% Dialysis $9.5 18%

Recent Acquisition – Aug 1, 2011 Endoscopy: Facilitate Accelerated Global Growth Minntech subsidiary acquired the assets of Byrne Medical, Inc. for $90.0M in cash and $10.0M in stock, plus $10.0M potential earnout Pre-acquisition revenues of ~$38.6M and EBIT of $11.5M Complementary: Further bolster our infection control presence and leadership in the gastroenterology suite Technology: precision performance disposables to reduce infection risk and complexities of sterilizing water bottles, tube sets, and valves IP protected product portfolio Market: sizeable, underpenetrated, global opportunity Early stages of shift to disposable being driven by Byrne Medical Customers: broaden reach from post-procedure cleaning (Medivators) into the treatment itself (Byrne Medical) Move closer to physician and operating nurses with preference items Sales Force: combined, the Endoscopy group now has over 80 field sales consultants and clinical specialists Exclusively focused on infection control in GI endoscopy Manufacturing: high-end engineering, design, production Utilize Byrne Medical facilities to create “Center of Excellence” for precision designed and manufactured disposable products Talent: Hired entire Byrne Medical team and refocused founder on product development and sales strategy. Smooth customer and employee transition

9 Medivators Plus Byrne Medical Endoscopy Segment: Complementary Businesses Intercept Wipes Veriscan Scope Buddy Intercept CER/DSD/ Advantage Rapicide Rapicide PA PROCEDURE ROOM Byrne Medical Products Treatment Room Physicians & Nurses Medivators Endoscope Reprocessing Products Principally in Post-Procedure, Reprocessing Area Sterile Processing Department / Nurses A/W/S Valves SmartCap / EndoGator

10 Cantel Medical Corp. Business Overview by Product, Customer, Channel Infection Prevention & Control Focus Healthcare & Life Sciences Orientation NYSE: CMN Renal / Dialysis Equipment, Sterilants, Consumables, Service Endoscopy Equipment, Disinfectants, Consumables, Service Dental Disposables Water Purification Equipment, Field Service, Consumables Specialty Packaging Packaging, Training PURIFICATION & FILTRATION IP&C DEVICE MGMT DISPOSABLES Therapeutic Filtration Hollow Fiber Filters Dialysis Chains Hospitals; GI Clinics/ASC’s Dental Offices Dialysis Clinics, Industrial Diverse Customer Set Hospitals, Biotech Firms Direct Sales Direct Sales Distributors Direct Sales & Distributors Direct Sales Distributors / OEM 1 5 4 8 1 1 Acquired2 90/10% 65/35% 100/0% 40/60% 100/0% 100/0% Consumable/ Capital1 1 Consumables includes service. Splits represent nine months ended 4/30/2011, inclusive of Byrne Medical acquisition. 2 Acquisition of Minntech Corporation in September 2001 is represented in Endoscopy, Renal/Dialysis, and Therapeutic Filtration

11 Cantel Medical Corp. Experienced Executive Team Andrew A. Krakauer President & CEO Former President of Ohmeda Medical (Division of Instrumentarium/GE) Over 20 years of healthcare experience Joined Cantel in 2004 as COO Craig A. Sheldon SVP, Chief Financial Officer & Treasurer Formerly with Ernst & Young LLP Certified Public Accountant Joined Cantel in 1994 Eric W. Nodiff SVP, General Counsel Former Partner at Dornbush Schaeffer Strongin & Venaglia, LLP Outside counsel to Cantel for 18 years Joined in-house in 2005 Seth R. Segel Executive Vice President Multiple years in Investment Banking, Strategy Consulting, and Global Operations Joined Cantel in 2002 Roy Malkin President & CEO, Minntech Over 25 Years in Healthcare Curtis Weitnauer President & CEO, Mar Cor Over 20 Years in Water Treatment Gary Steinberg CEO, Crosstex Over 20 Years in Dental Products

12 Cantel Medical Corp. Strong Performance Over the Past Two Years 1 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 2 Reflects abnormally large impact due to Novel H1N1 (“Swine”) flu sales of facemasks. 3 Last Twelve Months Cash flow from Operations less Capital Expenditures divided by average shares outstanding. LTM FREE Cash flow = $1.34/share3 Excluding any impact from Byrne Medical Acquisition on 8/1/2011 $6.2 $8.2 $3.2 $11.6 $7.1 $3.8 $6.5 $9.7 $8.1 Cashflow from Operations $16.0 $16.1 $16.0 $22.6 $19.2 $18.1 $23.1 $23.4 $22.3 Cash $30.0 $27.5 $33.0 $21.0 $25.0 $30.5 $38.0 $43.3 $49.3 Debt $0.29 $0.33 $0.29 $0.27 $0.25 $0.29 $0.37 $0.26 $0.25 Diluted EPS $5.0 $5.7 $5.0 $4.6 $4.3 $4.9 $6.2 $4.3 $4.2 Net Income $7.6 $8.9 $7.8 $7.5 $6.9 $8.0 $10.4 $7.5 $7.2 Operating Profit $11.7 $12.9 $11.5 $11.2 $10.4 $11.9 $14.0 $11.7 $10.8 EBITDAS1 37.9% 38.7% 39.2% 39.7% 40.1% 40.7% 41.5% 40.0% 38.4% Gross Margin $31.3 $31.4 $28.2 $27.7 $26.7 $27.1 $29.5 $26.7 $25.5 Gross Profit $82.6 $81.0 $72.0 $69.8 $66.6 $66.6 $71.0 $66.8 $66.4 Net Sales Q3'11 Q2'11 Q1'11 Q4'10 Q3'10 Q2'102 Q1'102 Q4'09 Q3'09 Apr Jan Oct Jul Apr Jan Oct Jul Apr Quarterly Financial Performance US Dollars Millions, except per share amounts Net Debt/(Cash) $27.0 $19.9 $14.9 $12.4 $5.8 ($1.6) $17.0 $11.4 $14.0

13 Cantel Medical Corp. Historical Income Statement Highlights 1 Reflects continuing operations and excludes any historical impact of Carsen Endoscopy & Surgical business. 2 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 3 Equivalent to “Income from Continuing Operations”. 4 Compound Annual Growth Rate. 5 Includes abnormally large financial impact from sales of facemasks during the H1N1 (“Swine”) Flu 6 LTM Byrne Medical at June 30, 2011 and Cantel Medical at April 30, 2011 $43.3 $59.8 $344.0 Pro Forma BMI Acquisition6 LTM

14 Cantel Medical Corp. Capacity for Continued Investment 1 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 2 Reclassified long-term debt as current liability due to expiration date of revolver. 3 Impact of $96M in debt used to acquired Byrne Medical. Sales and EBITDAS for Byrne is LTM 6/30/2011. Byrne Medical Impact3

15 Cantel Medical Corp. Significant Upside Growth Opportunities Substantial Sales & Marketing investments in core FY’09-FY’11 Substantial increase in R&D spending in FY’11 High-Margin Liquid Chemical Germicides (LCG) New chemistry development capabilities began mid-FY’10, accelerating in FY’11, to yield multiple New Product Introductions (NPI) in FY’12+ New General Manager and senior marketing executive added Expanded uses of existing chemistry products across all business segments Novel developments in fogging equipment and Revox sterilization services launched Antimicrobial coating and residual protection technology Odor eradication products Equipment and Disposables Endoscope reprocessors: broader portfolio, higher technology now with proprietary, “single-shot” chemistry launched worldwide Next generation water treatment equipment with focus on heat disinfection Unique disposables: Sure-Check® sterilization pouch & Secure-Fit™ face mask High value therapeutic filter developments underway Strong pipeline of future Byrne Medical products to be launched

16 Cantel Medical Corp. Significant Upside Growth Opportunities Acquisitions: 3 recent acquisitions, one in each core segment Byrne Medical has leadership position to drive a large, global market conversion to profitable disposable endoscopy components Continue solid integration and advancement on the acquisitions of Gambro Water and ConFirm Monitoring Proven ability to integrate, leverage and grow acquired businesses Robust pipeline of opportunities in disposables, endoscopy, and water purification Add to international and/or hospital channels New Markets – Alternative Channels Dedicated focus on corporate and government pandemic flu preparation (“Contagion”) One of only a few large U.S. manufacturers of FDA-cleared face masks Sponsored research study published demonstrating effectiveness of surgical facemasks vs. N-95 respirators (American Journal of Infection Control) Research evidencing reduced spread of disease using face masks as “source control” Specialized commercial / consumer markets for contract sterilization, fogging and residual protection technology Greater focus on promoting profitable and proprietary product lines internationally

Recent Acquisition in FY’11 Water Treatment Mar Cor Purification subsidiary acquired Gambro’s U.S. water treatment business (Oct 6, 2010) for $23.7M in cash. Pre-acquisition revenues of ~$14.0M. Strategic value akin to success of Mar Cor’s acquisition of GE’s Dialysis Water Business in March 2007. Technology: Industry Shift to Heat Disinfection and Growing Investment in Home Hemodialysis Acquired FDA-cleared heat disinfection central and portable systems to broaden the addressable customer base Installed Customer Base: Brought over 1,200 U.S. dialysis clinics and numerous hospitals to add consumables and service sales opportunities Manufacturing Scale Relocate production from Sweden to our Minnesota facility and create ~$0.5M through factory overhead absorption Customer Supply Agreement Unique supply contract position with a leading U.S. dialysis chain. Master data transitioned and we’re shipping orders Talent Hired all of Gambro’s U.S. aligned water personnel with expertise in dialysis and heat disinfection. Smooth customer transition

Recent Acquisition in FY’11 Healthcare Disposables Crosstex Int’l subsidiary acquired ConFirm Monitoring Systems’ sterility assurance business (Feb 14, 2011) for $7.5M in cash1. Pre-acquisition revenues of ~$4.0M. Product line extension to Crosstex’ key sterilization product category Position: #1 player in dental biological monitoring services in North America Industry guidelines call for weekly sterilizer testing. Canada now has two provinces shifting to daily testing Installed Customer Base: Key, long-term, private label distributor and dental school relationships as well as a solid branded business Direct contact with dentists daily Talent: Retained all of ConFirm’s aligned personnel with expertise in sterility assurance. Smooth customer transition. 1 Upfront cash purchase price. Up to an additional $1M of contingent cash consideration is possible based on achievement of sales levels for the twelve month period ending Jan 31, 2012.

Cantel Medical Corp. Strategic Evolution FY’04 – FY’08: Acquire and Define Infection Prevention & Control (IPC) Portfolio FY’09 – FY’10: Substantial Operational and P&L Improvement, while Investing in Sales & Marketing FY’11: Leverage Sales & Marketing and Drive R&D Investments. Close 1-2 Key Acquisitions EPS Range: $0.32-$0.53 EPS Range: $0.94-$1.18 (including H1N1 spike) $0.89-$1.05 (base business) FY’12+: Capitalize on all Strategic Investments (S&M, R&D, NPIs, Acquisitions) EPS Range: Significant Growth EPS Range: Solid Base Business Growth

Cantel Medical Corp. Formula: Acquire, Improve Businesses, Reload CAGR% 18% 23% ($25) $0 $25 $50 $75 $100 $125 $150 $175 $200 $225 $250 $275 $300 $325 $350 $ Millions Net Sales $94.0 $123.0 $137.2 $192.2 $219.0 $249.4 $260.1 $274.0 $344.0 EBITDAS $11.3 $14.0 $19.4 $26.5 $28.6 $31.8 $42.0 $47.5 $59.8 Net Debt/(Cash) ($3.7) $7.1 ($17.6) $8.1 $41.1 $40.0 $19.9 ($1.6) $109.9 EBITDAS Margin 12.0% 11.4% 14.1% 13.8% 13.0% 12.8% 16.2% 17.3% 17.4% FY'03 FY'04 FY'05 FY'06 FY'07 FY'08 FY'09 FY'10 Proforma LTM Q3'11 Phase I: Build Position; Grow EBITDAS [CAGR% 33%]; Improve Margin; Reduce Debt; Reload Phase II: Grow EBITDAS [CAGR% 20%]; Further Improve Margin; Reduce Debt, Reload

21 Cantel Medical Corp. Strategic Objectives Remain Focused within Infection Prevention & Control Near-term build a profitable $500 Million Specialty Business... setting the strategy for $1 Billion Achieve accelerated growth and profits from the three recent acquisitions Invest in higher technology, higher margin and higher growth organic programs with near-to-mid-term payoff High-value, unique IP&C disposables (e.g. Byrne Medical) Orientation around Liquid Chemical Germicides (LCG’s) Capital Equipment / Proprietary Consumable combination solutions Focus on channel expansion including flu preparation, hospital and international markets Substantial increased sales and marketing investments in base business Continue aggressive and proven acquisition program to leverage existing assets and channels Continue the program of Operational Excellence

22 Cantel Medical Corp. Summary Global, Growing ~$35B Market in Infection Prevention & Control Pure-play focus Fragmented nature creates opportunities for further growth and expansion $345M NYSE Specialty Infection Prevention & Control Leader1 Strong, recession-buffered core business with high future growth prospects 70% recurring revenue and $60M in trailing EBITDAS1 Successfully acquired 17 businesses since 2001 Substantial investments in new product development and increased sales and marketing capabilities Pristine record with the FDA, EPA and global regulatory bodies 90+% of products are made in the USA Strong cash flow and balance sheet (2.0x leverage ratio)1 $0.12/share annual dividend Selected for inclusion in the S&P SmallCap 600 Index 1 Pro forma for acquisition of Byrne Medical, Inc., which closed on August 1, 2011

 Cantel Medical Corp. (NYSE: CMN) Infection Control Matters™ CROSSTEX